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CCAAT/enhancer-binding protein delta (CEBPD) belongs to the CCAAT/enhancer-binding protein family, and these
proteins function as transcription factors in many biological processes, including cell differentiation, motility, growth
arrest, proliferation, cell death, metabolism and immune responses. The functional diversity of CEBPD depends, in
part, on the cell type and cellular context, which indicates that CEBPD could interpret a variety of cues to adjust cellular
responses in specific situations. Here, we review the regulation of the CEBPD gene and its function in response to
inflammatory stimuli. We also address its effects in inflammation-related diseases through a discussion of its recently
discovered downstream targets. Regarding to the previous discoveries and new insights in inflammation-associated
diseases, suggesting CEBPD could also be a central gene in inflammation. Importantly, the results of this study indicate
that the investigation of CEBPD could open a new avenue to help better understand the inflammatory response.Introduction
CCAAT/enhancer-binding protein delta (CEBPD) is an
intronless gene that encodes a 269-amino acid protein
belonging to the CCAAT/enhancer-binding protein family
of proteins, which are known to function as transcription
factors in cellular differentiation [1-3], metabolism [4] and
immune responses [5]. At present, six C/EBP members
have been identified in humans: CEBPA (C/EBP, RcC/
EBP-1), CEBPB (NF-IL6, LAP, CRP2, NF-M), CEBPG
(Ig/EBP-1), CEBPD (NF-IL6β, CRP3, CELF, RcC/EBP2),
CEBPE (CRP-1) and CEBPZ (CHOP-10, GADD153). All
of the members of this family contain very diverse N-
termini, a highly conserved (>90% identity) basic leucine
zipper domain and a basic domain for dimerization and
DNA binding at their C termini [6]. Moreover, several
posttranslational modifications, including acetylation,
sumoylation and phosphorylation were also identified
on C/EBP family members. Therefore, the highly con-
served DNA binding domains explain how C/EBP family
members can recognize similar DNA sequences in in vitro
and in vivo DNA binding assays [7-10] but show diverse
functions in cells, which may result from interaction with* Correspondence: yumingw@mail.ncku.edu.tw
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Review
Regulation of CEBPD expression during inflammation
The expression level of CEBPD is typically low in most
cells at normal physiological conditions but is rapidly
induced by external stimuli including glucocorticoids
[11-13], insulin [8,14,15] and growth factors, e.g., epidermal
growth factor [16]. In inflammatory environments, CEBPD
has been suggested to be activated by inflammatory factors,
such as interleukin-6 (IL-6) [17,18], lipopolysaccharides
(LPS) [19-25], interferon-α, interferon-γ (IFN-γ) [26],
tumor necrosis factor-α (TNFα) [27-30], prostaglandin E2
(PGE2) [31-33] and interleukin-1β (IL-1β) [6,29,30,34,35].
Although the above studies suggested that CEBPD con-
tributes to proinflammation, a study demonstrated that
CEBPD mediates in IFN-γ- and IL-1β- induced anti-
apoptosis and anti-inflammation in pancreatic β-cells
[36]. However, the details including signaling pathways
and responsive transcription factors in response to the
above stimuli to regulate the activation of CEBPD gene
remain less characterized.
In response to inflammatory stimuli, CEBPD gene tran-
scription can be activated through the phosphatidylinositol
3-kinase [37], p38 [16,30], JAK [18], JNK [21] and PKA [31]
signaling pathways. Interestingly, in addition to transcrip-
tional activation through the CEBPD promoter, a recentis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lated at both posttranscriptional and posttranslational
levels. In macrophages, nuclear HuR, an RNA-binding pro-
tein, responds to PGE2 and is shuttled to the cytoplasm to
stabilize CEBPD mRNA [32]. In addition, the E3 ubiquitin
ligase, seven in absentia homolog 2 (SIAH2), was suggested
to be involved in posttranslational regulation through the
polyubiquitination of CEBPD and downstream degradation
via the proteasome in breast cancer cells [38]. However, it
is still unclear whether this SIAH2-mediated degradation of
CEBPD commonly occurs in inflamed cells.
Role of CEBPD in cyclooxygenase 2 (COX-2) regulation
Prostaglandins play important roles in many biological
processes, including cell division, immune responses,
blood pressure regulation, ovulation, bone development
and wound healing [39]. Prostaglandin-endoperoxide
synthase 2, also known as COX-2, is an inducible enzyme
whose expression is mainly regulated at the transcription
level and can be induced by cytokines, growth factors,
phorbol esters and endotoxins. In the past decade, tre-
mendous progress has been made in understanding the
functional roles of COX-2 in cell growth, cell death, cell
motility and tumorigenesis. C/EBP family members have
been suggested to be involved in regulating COX-2 tran-
scription through direct binding to the promoter region of
the COX-2 gene. CEBPB and CEBPD bind to the COX-2
promoter in chondrocytes following IL-1β treatment [40].
Moreover, mouse CEBPD (Cebpd) is involved in LPS- and
proteasome inhibitor-induced COX-2 gene expression in
murine RAW 264.7 macrophages and alveolar epithelial
cells, respectively [41,42]. Interestingly, prostaglandin E2
(PGE2), a COX-2 enzymatic product, can induce CEBPD
gene expression [32] (Wang JM et al., unpublished results).
These results suggested that the regulation of COX-2 and
CEBPD could be functioning in a positive-feedback loop.
On the other hand, the activation of p38 mitogen-activated
protein kinase (MAPK) has been observed in response to
IL-1β or TNFα treatment [43-45] and has been suggested
to be involved in the activation of CEBPD transcription
[46,47]. However, whether p38-mediated CEBPD activation
commonly participates in COX-2 gene regulation in
inflamed cells remains an open question and needs to
be further clarified.
In our previous study, we also showed that the post-
translational modification of CEBPD is involved in COX-2
regulation. The sumoylated-LAP1 (CEBPB variant) and
CEBPD both act as mediators in modulating HDAC4
recruitment on the COX-2 promoter. Upon EGF treat-
ment, the instantly induced nonsumoylated CEBPD can
be a positive regulator that replaces the sumoylated-LAP1
and CEBPD. This replacement will increase the p300
binding and form an intact initiation of the activation
complex to stimulate COX-2 transcription [9]. Thesestudies indicated that the post-translational modifications
of CEBPD protein also responsible for CEBPD-mediated
transcriptional regulation. In addition, the histone deace-
tylase inhibitor, trichostatin A, has a positive effect on
LPS-induced COX-2 transcription. It was suggested to be
regulated by increasing the recruitment of CEBPA and
CEBPB, but not CEBPD, to the COX-2 promoter because
the CEBPD expression was attenuated [48].
The roles of CEBPD during acute inflammation
Activation of CEBPD has been observed in several acute
inflammation diseases. However, the detailed mechanisms
and regulations involving CEBPD need to be studied
extensively. The acute-phase response (APR) protein takes
part in the early and nonspecific (but highly complex)
reaction of an organism in response to a variety of injuries,
such as bacterial infection, tissue injury, extensive bleed-
ing, LPS, turpentine oil, heavy metals, thermal injury or
surgery [19,49,50]. The liver has been believed to play an
important role in the production of APR during the early
stages of acute inflammation. CEBPA, CEBPB and CEBPD
were reported to regulate APR expression in liver cells
[17,51]. Poli et al. demonstrated that the CEBPs involved
in the induction of APR genes are linked to newly synthe-
sized, NF-κB- and STAT3-regulated CEBPB and CEBPD
proteins [35]. Moreover, phosphorylated CEBPD mediates
serum amyloid A gene expression in APR-induced inflam-
mation in rabbit liver [52].
NF-κB has long been considered to be involved in the
prototypical proinflammatory response that is largely
based on the role of NF-κB in the induction of proin-
flammatory cytokines, chemokines and adhesion mole-
cules. CEBPD can crosstalk with NF-κB in inflamed and
immune cells. In Toll-like receptor 4 (TLR4)-induced
macrophage activation, NF-κB binds to the CEBPD pro-
moter and activates CEBPD transcription. Then, CEBPD
binds to the IL-6 promoter and cooperates with NF-κB
to fully activate IL-6 transcription [53]. CEBPD also can
act as an amplifier of NF-κB-mediated transcription,
which discriminates transient and persistent TLR4 signals,
thus facilitating the sustained expression of the inflamma-
tory response [53]. In addition, a recent study showed
that CEBPD activates TLR4 gene expression in macro-
phages and a CEBPD downstream target, F-box and
WD repeat domain containing protein 7 alpha, would
feedback negatively and downregulate CEBPD to attenu-
ate TLR4 inflammatory signaling [22]. These discoveries
suggest that TLR4 and CEBPD could form a regulatory
loop in macrophages.
In addition to the classical NF-κB and MAPK pathways,
LPS was shown to activate IκB kinase ε, leading to the
phosphorylation and activation of CEBPD [23]. However,
it has also been reported that low-dose LPS fails to acti-
vate the classical NF-κB pathway and contributes to the
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Selectively removing the suppressive nuclear receptors,
including peroxisome proliferator-activated receptor α
and retinoic acid receptor, on the promoter regions
of proinflammatory mediators activates CEBPD in an
interleukin-1 receptor-associated kinase 1-dependent
manner [24]. As a critical mediator of LPS-induced acute
lung injury, CEBPD can be repressed by the transcription
factor Miz1 through recruiting the histone deacetylase
HDAC1, further contributing to the suppression of in-
flammation [54,55]. Meanwhile, suppressor of cytokine
signaling 3, a negative regulator of IL-6 signaling, has a
protective role in LPS-induced acute lung injury by
suppressing CEBPD activity [56]. CEBPD-dependent
macrophage mobilization also plays a key role in con-
tributing to the host’s defense against bacterial infection
[57] and exaggerates bacterial dissemination through
platelet-activating factor receptor-dependent bacterial
translocation in pulmonary infection [58]. In addition,
Cebpb- or Cebpd-deficient macrophages showed impaired
induction of IL-6 and TNFα stimulated by several TLR
ligands [54,59,60]. Furthermore, both CEBPB and CEBPD
are key transcription factors that regulate the Fcγ
receptor-mediated induction of TNFα, macrophage in-
flammatory protein 2 and 1α in macrophages [61].
Induction of disseminated intravascular coagulation in
CEBPD-deficient mice decreased endotoxin-induced
systemic inflammation when compared with wild-type
mice, as evident from the decreased plasma levels of
tumor necrosis factor-alpha and IL-6 [62]. On the other
hand, CEBPD mediated the activation of the LPS-
induced anti-inflammatory factor interleukin 10 in mouse
macrophages [21]. Our results showed that CEBPD
expression can be induced in both M1 and M2 macro-
phages (Wang JM et al. unpublished results). These
findings implied that CEBPD could interact with different
components in response to various inflammatory cyto-
kines and plays opposite roles in initiating and resolving
the inflammatory response. Interestingly, miR let-7c,
which targets CEBPD, has been clarified in promoting M1
macrophage polarization and diminishing M2 phenotype
expression [25]. This study further noted the possibility
that CEBPD could play a regulator to switch the M1/M2
population during inflammation. Taken together, the
above discoveries and controversial observations imply that
CEBPD possesses a dual role in immunity/inflammation
reactions and indicates that the dissection and interpret-
ation of CEBPD’s function during inflammation is complex.
CEBPD during neuroinflammation and inflammation-
related diseases
Despite the large amount of studies that have been
conducted and the solutions that have been proposed for
clinical applications in chronic inflammatory diseases, ourknowledge base is still not sufficient to effectively treat
these diseases. Thus, the identification and investigation
of novel or less-characterized, inflammation-related genes
are important. The activation of CEBPD has been ob-
served in many autoimmune and age-associated chronic
inflammation diseases, such as atherosclerosis [63], type 2
diabetes [64], rheumatoid arthritis (RA) [65], Alzheimer’s
disease (AD) [66] and Parkinson’s disease [67]. Recently, a
more detailed involvement of CEBPD in some of these
inflammation-related diseases, and even in the tumor
microenvironment, has been elucidated.
CEBPD in AD
Though the increased levels of CEBPA and CEBPB at
sites of neuroinflammation or neural damage have been
mentioned [68], the identification and function of CEBP-
mediated transcriptional regulation and the target genes
remain rarely investigated. An immunohistochemistry assay
revealed that the location of CEBPD is consistent with the
cytokine-laden milieu of the AD neocortex and limbic
cortex, and CEBPD is qualitatively more abundant and
stains intensely in astrocytes of AD patients [66]. This
observation raised several interesting questions, including
whether the impairment in memory and cognition as well
as the personality change, all of which are characteristics
of AD patients, are due to the increased levels of CEBPD
in astrocytes.
Activated phagocytic microglia also interact with astro-
cytes and neural cells to fight off infections as quickly as
possible with minimal damage to healthy brain cells. In
AD, phagocytic microglia travel to the site of injury in the
inflamed brain to engulf the offending materials. We
found that astrocytic CEBPD has the ability to attenuate
macrophage-mediated phagocytosis of damaged neurons.
One CEBPD target, pentraxin-3 (PTX3, also known as
TNFAIP5 or TSG-14), participates in the attenuation of
macrophage-mediated phagocytosis of damaged neurons
[29]. These results provided the first molecular evidence
indicating that astrocytic CEBPD and CEBPD-regulated
PTX3 play a role in the accumulation of damaged neurons
and repair of brain damage. It was also suggested that the
detection of PTX3 in cerebrospinal fluid could be used as
a diagnostic tool for AD progression. Moreover, CEBPD
also regulates the chemoattractive factor gene monocyte
chemotactic protein-1 (MCP-1) and the migration-
promoting genes matrix metalloproteinase (MMP)-1
and MMP-3. Once astrocytic CEBPD is induced by IL-1β,
the recovered GSK3β activity phosphorylates CEBPD at
serine 167 (ser167), which then promotes the migration
and activation of microglia/macrophages [30] through
MCP-1 and MMP-1, respectively. Meanwhile, the use of
the GSK3β inhibitor LiCl in this study suggested that the
effect of LiCl in the clinic may not only act on neural cells
but could also result from the inhibition of CEBPD in
Ko et al. Journal of Biomedical Science  (2015) 22:6 Page 4 of 8astrocytes. Furthermore, an increase in apoptotic astrocytes
was observed in AppTg/Cebpd−/− mice [an Alzheimer
disease mouse model (APPswe/PS1/E9 bigenic) crossed
with Cebpd-deficient mice], thereby suggesting that CEBPD
plays a functional role in contributing to the anti-apoptotic
ability of astrocytes [69]. The Zinc Finger Protein 179
(ZNF179) gene is activated by CEBPD and mediates
CEBPD-induced anti-apoptosis in astrocytes by collaborat-
ing with the transcription repressor PLZF to inactivate the
expression of the proapoptotic genes insulin-like growth
factor-binding protein 3 and BCL2-interacting killer [69].
The biological function of CEBPD and its downstream
target genes in astrocytes are indicated in Figure 1.
CEBPD in Traumatic brain injury (TBI)
TBI is also known to increase the expression of amyloid
precursor protein (APP) [70]. Many studies have reported
that TBI-induced Aβ accumulation can further contribute
to AD formation [71,72], but the detailed mechanisms of
TBI progression and its association with AD formation
remain less characterized. CEBPD has been reported to be
upregulated in the cortex of TBI rats [73]. As mentioned
above, Ko et al. showed that astrocytic CEBPD levels
increase in response to Aβ and proinflammatory factors
[29]. Therefore, CEBPD could be the link between TBI-
induced Aβ accumulation and AD pathogenesis. However,
this speculation requires further study. In addition, indu-
cible nitric oxide synthase (iNOS) deficiency prevented
beta-amyloid deposition, astrocytosis, microgliosis and
disease progression in APPTg mice [74]. CEBPD also
upregulates neurotoxic iNOS expression in glial cells [75].
In Cebpd−/− mice, systemic LPS-induced brain expression
of iNOS, TNFα, IL-1β and IL-6 was attenuated [76]. These
results demonstrated that CEBPD plays a crucial role in
regulating proinflammatory gene expression in glial acti-








Figure 1 Functional roles of astrocytic CEBPD.relevance of the roles of glial CEBPD and iNOS in neuro-
inflammation diseases, including TBI, remain unclear.
CEBPD in RA
Coincident with the increased levels of serum C-reactive
protein and synovial IL-6, increased CEBPB and CEBPD
expression was detected in synovial tissue of patients
with RA [65]. Macrophages have been suggested to play
a central immunoreactive role in RA [77,78] due to their
prominent numbers at the cartilage-pannus junction. In
RA, CEBPD expression was mainly observed in macro-
phages [65] and compared with WT mice, reduced pannus
formation and greater joint architecture integrity were
observed in the paws of collagen-induced arthritis Cebpd-
deficient mice [79]. Using cytokine array and microarray
analyses, we identified several secretory factors, including
chemokine (C-C motif) ligand 20 (CCL20), chemokine (C-
X-C motif) ligand 1 (CXCL1), IL-23A and tumor necrosis
factor alpha-induced protein 6 (TNFAIP6), that were
directly regulated by CEBPD in macrophages [79]. A loss of
function assay showed that CCL20, IL23A, CXCL1 and
TNFAIP6 contributed to the migration and proliferation of
synoviocytes, but only the latter two proteins were involved
in the tube formation of endothelial cells [79]. Interestingly,
two potent anti-inflammatory molecules, inotilone and
rosmanol [80,81], which are putative CEBPD inhibitors,
were shown to inhibit the migration and proliferation of rat
fibroblast-like synoviocytes as well as the tube formation of
HUVECs [79]. Taken together, the elucidation of CEBPD
biology and its downstream effectors could be helpful in
the diagnosis of RA, and these factors could potentially
serve as therapeutic targets for RA therapy.
CEBPD in multiple sclerosis (MS)
As an autoimmune inflammatory disease, MS is the
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and variable axonal loss. It is characterized by multiple
lesions (plaques) involving the brain and spinal cord and
has an unpredictable clinical course. Experimental auto-
immune encephalomyelitis (EAE) is the most commonly
used experimental model for the human inflammatory
demyelinating disease, MS. Mice deficient in Cebpd
expression exhibited less severe clinical disease than
wild-type littermates in response to induction of EAE by
vaccination with a myelin oligodendrocyte glycoprotein
fragment [82]. This study suggested that CEBPD suppresses
expression of IL-10 in dendritic cells (DC), favoring
Th17 over Treg development. These findings indicated
that CEBPD plays a functional role in both DC and
CNS autoimmune inflammatory disease via altering the
Th17:Treg balance in an IL-10 dependent fashion.
The role of CEBPD in macrophages of the tumor
microenvironment
Epidemiological studies and animal experiments have
suggested that inflammation can increase the risk of
normal cells developing into tumorigenic cells as well as
enhance cancer cell invasion and metastasis. Moreover,
the microenvironment of solid tumors is characterized by
a reactive stroma containing an abundance of inflamma-
tory mediators, leukocytes, dysregulated vessels and pro-
teolytic enzymes. However, the communication between
cancer cells and the surrounding stromal cells, such as
macrophages and fibroblasts, remains largely unclear,
especially in an inflammation condition.
Tumor-associated macrophages (TAMs), a type of stro-
mal cell, play a crucial role in promoting the progression
of certain cancers. TAMs have an M2 phenotype and
function in the promotion of tumor cell proliferation,
angiogenesis and constitutive matrix turnover as well as in







Figure 2 CEBPD in tumor-associated macrophages (M2 Mϕ).promoting properties of macrophages have been further
revealed due to their ability to synthesize and secrete
inhibitory factors that suppress anti-tumor effectors of
the host. COX-2 is commonly activated in cancer cells,
resulting in the production of PGE2, which exerts strong
immunosuppressive effects on cell-mediated immune
mechanisms [85,86].
One study demonstrated that Cebpd−/−/HER2/neu mice
exhibit increased mammary tumor multiplicity and
decreased lung metastasis [87]. The study agreed with
the speculation that CEBPD acts as a tumor suppressor
in cancer cells [88]. In addition, the hypoxia environment
in cancer can induce CEBPD expression and contributes
to the metastasis and invasion of cancer cells [87]. Actu-
ally, the decreased lung metastasis may also implied that
the existence of CEBPD in stromal cells, such as fibro-
blasts or macrophages, in tumor microenvironment might
contribute to invasion/metastasis. We found that CEBPD
regulates or co-regulates a wide range of inflammatory
factors, such as TNFα, IL-1β, IL-6, CXCL1, IL-17A [79],
and the chemokines, monocyte chemoattractant protein 1
(MCP1) and IL-10 [30,32,89]. Therefore, several inter-
esting and valuable issues were raised and should be
addressed including (I) an investigation of the regulation
of CEBPD expression in the cells surrounding a tumor,
such as TAMs, and (II) a dissection of the contributions of
CEBPD and the consequent effects of its activation within
the tumor microenvironment.
As mentioned above, CEBPD directly regulates COX-2
gene expression [46]. We also demonstrated that PGE2
positively regulated CEBPD expression through HuR-
mediated posttranscriptional regulation in macrophages.
Moreover, a cancer cell allograft mouse model provided
evidence to support the idea that CEBPD plays a role in
cancer growth in the protumor microenvironment [32].
Importantly, in TAMs, the CEBPD downstream targetprotumor effect
D
IL-10 adaptive immunity 
PTX3 phagocytosis
CEBPD
target genes cellular responses
Ko et al. Journal of Biomedical Science  (2015) 22:6 Page 6 of 8PTX3 and IL-10 were shown to suppress the ability of
macrophages to phagocytose cancer cells and provide
immunosuppressive effect, respectively [32]. The functional
roles of PGE2-induced CEBPD in macrophages of the
tumor microenvironment are shown in Figure 2. This
study successfully revealed a new insight of CEBPD in the
communication between cancer cells and the tumor mic-
roenvironment, especially in macrophages. Moreover, the
results of this study also implied that the dissection of
CEBPD’s roles in the tumor microenvironment could pro-
vide a great opportunity to develop a feasible translational
application for cancer therapy.Conclusion
In this review, we highlighted the role of CEBPD during
inflammation and inflammation-related diseases, includ-
ing cancers. Recent studies have partly revealed the roles
of CEBPD in inflammation and have uncovered much
about CEBPD biology, especially in various cell types;
however, the effects of these roles and their crosstalk
between different cell types remain largely unknown. In
addition, we know that posttranslational modification of
proteins plays an important role in the precise function
and correct response of cells to external stimuli; how-
ever, how these posttranslational modifications affect
the function of CEBPD or how specific proteins interact
with CEBPD and affect CEBPD’s roles in cell-type-
specific manners is still unknown. CEBPD has been linked
to many cellular functions and inflammatory diseases.
Therefore, new insights into CEBPD’s involvement and
regulation will be helpful to better understand the com-
plexity and diversity of inflammatory processes and will
also identify targets for the development of therapeutic
drugs and strategies to overcome inflammation-related
diseases involving CEBPD.Competing interests
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